Resources|Events|April 2, 2026

SCOPE X 2026

Listen

0:00 / 0:00

SCOPE X is the newest addition to the trusted SCOPE 365 portfolio, created for clinical research executives and thought leaders who want to go beyond the surface and dive deeply into how advanced data strategies and artificial intelligence are transforming clinical research.

This intimate, two-day gathering being held in Boston, the center of biopharma investment and innovation, brings together clinical research leaders, clin ops execs, heads of clinical data services, data scientists, technology innovators, AI start-ups, and experts for focused conversations on solving the industry’s most pressing challenges.

This includes two programs: AI and Data Clinical Trial Optimization and AI Strategy and Business Value in Clinical Development, as well as an interactive Short Course.

Expect highly interactive sessions, detailed case studies, and collaborative problem-solving designed to spark actionable ideas you can implement in practice in these programs. You’ll connect with peers driving innovation in:

Integrating and optimizing diverse data sources
Implementing AI-ready data strategies
Applying AI for trial design, monitoring, and decision-making
Harnessing agentic AI for clinical trials transformation
Addressing AI-related governance, and ethical considerations

With a curated program and a collaborative setting, SCOPE X offers the kind of in-depth exchange and high-value networking that’s hard to find at larger events. If you’re serious about advancing your data and AI capabilities, this is where you want to be in May 2026.

May 18-19, 2026

Omni Boston Hotel at the Seaport
450 Summer Street
Boston, MA 02210

https://www.scopesummit.com/scopex

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 6th, 2026

What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

November 6th, 2026

ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Ten key risk indicators can flag recurring good clinical practice problems in noncompliance, safety, data quality, and oversight, but only when normalization, trial timing, and combined signals are taken into account. Credit: Stock.Adobe.com/Andrey Popov.

November 6th, 2026

The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

November 5th, 2026

Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

November 5th, 2026

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

November 5th, 2026

ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal

In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.

November 4th, 2026

Comparing OpenAI and Mistral on Clinical Trial Matching

Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.

November 4th, 2026

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time

In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.